Inactivation of eIF4A appears to concomitantly target several key pathways involved in proliferation and cell survival of MYCN amplified neuroblastoma, making eIF4A a highly attractive target for the treatment of MYCN-amplified tumours. Here, EIF4A1 is linked to neoplasm.